{
    "clinical_study": {
        "@rank": "48733", 
        "acronym": "GPTVT", 
        "arm_group": [
            {
                "arm_group_label": "Aurolab glaucoma drainage device", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Trabeculectomy with mitomycin-c", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "Medical treatment of glaucoma in West Africa is often unsuccessful because of the cost of\n      medications, disease severity and poor compliance. Surgical treatment is likely to be a more\n      practical solution.\n\n      The purpose of this study is to compare the safety and efficacy of the Aurolab glaucoma\n      drainage device against trabeculectomy with mitomycin-c in a prospective randomised surgical\n      study."
        }, 
        "brief_title": "The Ghana Primary Tube Versus Trabeculectomy Study", 
        "condition": "Glaucoma", 
        "condition_browse": {
            "mesh_term": "Glaucoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Age 18 to 85 years, inclusive\n\n          -  Open angle glaucoma. Including primary open angle glaucoma, pseudoexfoliative and\n             pigmentary glaucoma\n\n          -  Intraocular pressure 18 - 40 mmHg on maximal tolerated or maximal affordable medical\n             therapy\n\n          -  Informed consent given and consent form signed.\n\n        Exclusion Criteria:\n\n          -  Unwilling or unable to give consent, unwilling to accept randomisation, or unable to\n             return for scheduled protocol visits\n\n          -  Pregnant or nursing women\n\n          -  No light perception vision\n\n          -  Previous incisional intraocular surgery, other than uncomplicated clear corneal\n             cataract surgery\n\n          -  Previous ocular laser in study eye\n\n          -  Iris neovascularisation or proliferative retinopathy\n\n          -  Primary angle closure or primary angle closure glaucoma\n\n          -  Iridocorneal endothelial syndrome or anterior segment dysgenesis\n\n          -  Epithelial or fibrous downgrowth\n\n          -  Aphakia\n\n          -  Chronic or recurrent uveitis\n\n          -  Steroid-induced glaucoma\n\n          -  Severe posterior blepharitis\n\n          -  Unwilling to discontinue contact lens use after surgery\n\n          -  Previous cyclodestructive procedure\n\n          -  Glaucoma secondary to penetrating keratoplasty, trauma, retinal disease/surgery or\n             neovascular disease\n\n          -  Conjunctival scarring from prior ocular surgery, trauma or cicatrizing disease\n             precluding a superior trabeculectomy\n\n          -  Need for glaucoma surgery combined with other ocular procedures (i.e. cataract\n             surgery, penetrating keratoplasty, or retinal surgery) or anticipated need for urgent\n             additional ocular surgery"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "85 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "298", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 11, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02088528", 
            "org_study_id": "TCEC 044/13-14"
        }, 
        "intervention": [
            {
                "arm_group_label": "Aurolab glaucoma drainage device", 
                "description": "Patients undergoing surgery will receive an implant", 
                "intervention_name": "Aurolab glaucoma drainage device", 
                "intervention_type": "Device", 
                "other_name": "AADI"
            }, 
            {
                "arm_group_label": "Trabeculectomy with mitomycin-c", 
                "description": "Trabeculectomy surgery augmented by application of mitomycin C (0.4 mg/ml) to the sclera in the region of the trabeculectomy site for a period of exactly 3 minutes.", 
                "intervention_name": "Trabeculectomy with mitomycin-c", 
                "intervention_type": "Procedure"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Mitomycins", 
                "Mitomycin"
            ]
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "March 14, 2014", 
        "link": {
            "url": "http://www.gptvt.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Tema", 
                    "country": "Ghana"
                }, 
                "name": "Tema Christian Eye Center"
            }, 
            "investigator": {
                "last_name": "Alexander Spratt, MBBCh FRCOphth", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "Ghana"
        }, 
        "number_of_arms": "2", 
        "official_title": "The Ghana Primary Tube Versus Trabeculectomy Study", 
        "other_outcome": {
            "measure": "Patient satisfaction with communications by text message", 
            "safety_issue": "No", 
            "time_frame": "1 week, 1 month, 3 months, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years"
        }, 
        "overall_contact": {
            "email": "mail@gptvt.com", 
            "last_name": "Alexander Spratt, MBBCh FRCOphth", 
            "phone": "+233549446981"
        }, 
        "overall_official": [
            {
                "affiliation": "Tema Christian Eye Center", 
                "last_name": "Alexander Spratt, MBBCh FRCOphth", 
                "role": "Principal Investigator"
            }, 
            {
                "affiliation": "Moorfields Eye Hospital NHS Foundation Trust", 
                "last_name": "Keith Barton, MBBCh MD FRCP FRCOphth", 
                "role": "Study Chair"
            }, 
            {
                "affiliation": "University of North Carolina, Chapel Hill", 
                "last_name": "Donald L Budenz, MD MPH", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Ghana: The Food and Drugs Authority", 
            "has_dmc": "Yes"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "March 2021", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change in intraocular pressure", 
            "safety_issue": "No", 
            "time_frame": "3 months, 6 months, 1 year, 18 months, 2 years, 2\u00bd years, 3 years, 3\u00bd years, 4 years, 4\u00bd years, 5 years"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02088528"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Tema Christian Eye Center", 
            "investigator_full_name": "Alex Spratt", 
            "investigator_title": "Principal Investigator", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Complication rates", 
                "safety_issue": "Yes", 
                "time_frame": "1 day, 1 week, 1 month, 3 months, 6 months, 1 year, 18 months, 2 years, 2\u00bd years, 3 years, 3\u00bd years, 4 years, 4\u00bd years, 5 years"
            }, 
            {
                "measure": "Visual acuity", 
                "safety_issue": "Yes", 
                "time_frame": "1 day, 1 week, 1 month, 3 months, 6 months, 1 year, 18 months, 2 years, 2\u00bd years, 3 years, 3\u00bd years, 4 years, 4\u00bd years, 5 years"
            }, 
            {
                "measure": "Visual field", 
                "safety_issue": "Yes", 
                "time_frame": "6 months, 1 year, 2 years, 3 years, 4 years, 5 years"
            }, 
            {
                "measure": "Reoperation for glaucoma", 
                "safety_issue": "No", 
                "time_frame": "1 day, 1 week, 1 month, 3 months, 6 months, 1 year, 18 months, 2 years, 2\u00bd years, 3 years, 3\u00bd years, 4 years, 4\u00bd years, 5 years"
            }, 
            {
                "measure": "Supplemental medical therapy", 
                "safety_issue": "No", 
                "time_frame": "1 day, 1 week, 1 month, 3 months, 6 months, 1 year, 18 months, 2 years, 2\u00bd years, 3 years, 3\u00bd years, 4 years, 4\u00bd years, 5 years"
            }, 
            {
                "measure": "Quality of life", 
                "safety_issue": "No", 
                "time_frame": "1 week, 1 month, 3 months, 6 months, 1 year, 2 years, 3 years, 4 years, 5 years"
            }
        ], 
        "source": "Tema Christian Eye Center", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "International Glaucoma Association", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "HCA International Foundation", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "Tema Christian Eye Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}